AZT modulation of trimetrexate myelotoxicity: evidence from an HL60 model.
AZT is widely used in combination with other potentially myelotoxic drugs. Bone marrow suppression may limit the vigor of therapy directed at HIV itself, opportunistic infections, and/or AIDS-associated malignancies. Evidence from an HL60 model suggests that toxicity is of most concern with simultaneous use of multiple agents, and that staggered use of different agents may in some cases be a more effective strategy.
Nusbaum
N J
NJ
DWH Hematology/Oncology Complex Brookdale Hospital Medical Center, Brooklyn, N.Y. 11212 USA.
Abraham
T
T
D000163:Acquired Immunodeficiency Syndrome / Q000378:metabolism; D006801:Humans; D007951:Leukemia, Myeloid / Q000378:metabolism; D008954:Models, Biological; D016597:Trimetrexate / Q000494:pharmacology*; D014407:Tumor Cells, Cultured / Q000187:drug effects*; D015215:Zidovudine / Q000494:pharmacology*
D015215:Zidovudine; D016597:Trimetrexate